BIOLOGICS OUTSOURCING MARKET ANALYSIS
Restraints & Challenges:
Global Biologics Outsourcing Market: Restraint
Technical and Logistics challenges
Increasing focus on in-house biologics manufacturing is expected to act as a restraint for the growth of the global biologics outsourcing market over the forecast period. For instance, on February 15, 2023, Genentech, a biotechnology company, announced the construction of new small-batch biologics manufacturing facility in California, U.S., which will be operational in early 2025. The new facility will be the first commercial biopharma manufacturing facility to incorporate the latest manufacturing technologies along with in-house process improvements for increased flexibility, speed, and output under one roof. The new facility is designed for the commercial production of biologics for smaller patient populations, including rare diseases and personalized medicines.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
